TF and acute myeloid leukemia: As downmodulation of miR‐29b correlates with different pathologies, a number of delivery systems for exogenous miR‐29b have been generated.10, 11, 12, 13 Concerning AML, a transferrin‐conjugated nanoparticle method was developed to increase miR‐29b in AML blasts.14 However, despite its efficacy in in vivo AML models, this approach is not clinically available at present and activation of transcriptional expression may constitute an efficient therapeutic strategy for restoring the miR‐29b level in myeloid leukaemia.